Hum. Reprod. Advance Access originally published online on June 24, 2004
Human Reproduction 2004 19(8):1871-1876; doi:10.1093/humrep/deh312
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Use of the concomitant serum dosage of CA 125, CA 19-9 and interleukin-6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions
1 Department of Obstetrics and Gynecology, Clinica ‘L.Mangiagalli’, University of Milano, 2 Istituto Auxologico Italiano and 3 Laboratorio di Chimica Clinica Istituti Clinici di Perfezionamento Milano, MilanoItaly
4 To whom correspondence should be addressed at: Department of Obstetrics and Gynecology, Clinica ‘L.Mangiagalli’, Via Commenda 12, Milano, 20122, Italy. Email: dadosomigliana{at}yahoo.it
BACKGROUND: Recent studies have proposed the measurement of CA 19-9 and IL-6 as an alternative to CA 125 as markers for endometriosis. This study was performed in order to verify the clinical value of serum CA 125, CA 19-9 and IL-6 levels, either by themselves or combined, in the detection of the disease. METHODS: In a prospective cohort study, serum concentrations of CA 125, CA 19-9 and IL-6 were measured in a consecutive series of 80 women of reproductive age who underwent laparoscopy for benign gynaecological pathologies. RESULTS: Endometriosis was documented in 45 women (stage I–II in 14 cases and stage III–IV in 31 cases). Patients with endometriosis had significantly higher levels of CA 125 than controls [23.4 IU/ml (13.3–37.6) versus 11.4 IU/ml (9.1–18.5), P<0.001)]. Conversely, women with and without the disease were shown to have similar levels of both IL-6 pg/ml [0.6 (undetectable–1.4) versus 1.0 pg/ml (0.4–1.9), P=0.09] and CA 19-9 [9.8 IU/ml (4.5–20.8) versus 7.4 IU/ml (2.8–11.5), P=0.11]. The area under the receiver operating characteristics curve resulted in a statistically significant difference from the null hypothesis only for CA 125 (P<0.001). Sensitivity and specificity of CA 125 were 27 and 97% respectively and were higher than those related to CA 19-9 and IL-6. Concomitant use of the three dosages led to a sensitivity and a specificity of 42 and 71% respectively. CONCLUSIONS: The concomitant dosage of CA 125, CA 19-9 and IL-6 does not add significant information in respect to the CA 125 test alone in diagnosing either early or advanced stages of endometriosis.
Key words: diagnosis/endometriosis/CA 125/CA 19-9/IL-6
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Agic, S. Djalali, M. M. Wolfler, G. Halis, K. Diedrich, and D. Hornung Combination of CCR1 mRNA, MCP1, and CA125 Measurements in Peripheral Blood as a Diagnostic Test for Endometriosis Reproductive Sciences, November 1, 2008; 15(9): 906 - 911. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Van Calster, D. Timmerman, T. Bourne, A. C. Testa, C. Van Holsbeke, E. Domali, D. Jurkovic, P. Neven, S. Van Huffel, and L. Valentin Discrimination Between Benign and Malignant Adnexal Masses by Specialist Ultrasound Examination Versus Serum CA-125 J Natl Cancer Inst, November 21, 2007; 99(22): 1706 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Martinez, N. Garrido, J.L. Coperias, F. Pardo, J. Desco, J.A. Garcia-Velasco, C. Simon, and A. Pellicer Serum interleukin-6 levels are elevated in women with minimal-mild endometriosis Hum. Reprod., March 1, 2007; 22(3): 836 - 842. [Abstract] [Full Text] [PDF]
|
|